NCT02014506 - Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions

Haploidentical Hematopoietic Stem Cell TransplantationMalignant DiseaseNon-malignant Disease

Interventions

DRUG

Fludarabine

40mg/M2 once daily IV on days -7 to -2

DRUG

Cyclophosphamide

50 mg/kg IV on day -3 and -2

BIOLOGICAL

anti-thymocyte globulin

BIOLOGICAL

filgrastim

Beginning on day 4 and continuing until blood counts recover

RADIATION

Total body irradiation

200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 \& -4 (severe aplastic anemia)

PROCEDURE

TCRαβ-depleted hematopoietic cell transplantation

DEVICE

CliniMACS

Immunogenetic depletion of TCRαβ cells

Trial Locations (1)

RECRUITING

Asan Medical Center, Seoul